Nhua Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 741 million yuan, up 5.74% from the same period last year. Total operating revenue was 3.218 billion yuan, up 6.91% year-on-year, marking five consecutive years of growth. Net cash inflow from operating activities was 280 million yuan, down 43.33% year-on-year. The company's latest asset-liability ratio was 12.30%, gross margin was 73.86%, and diluted earnings per share was 0.73 yuan.
Jiangsu Nhwa Pharmaceutical Co LtdNet profit up 5.74% and revenue up 6.91% in interim report.
